<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To investigate the neuroprotective potential of the Src family kinase (SFK) inhibitor 4-amino-5-(4-chlorophenyl)-7-(<z:chebi fb="0" ids="30355">t-butyl</z:chebi>) pyrazolo(3,4-d)<z:chebi fb="0" ids="16898">pyrimidine</z:chebi> (PP2) in transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in the rat </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: Sprague-Dawley rats were exposed to transient (90 min) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) and evaluated after 1 day of survival </plain></SENT>
<SENT sid="2" pm="."><plain>PP2 (1.5 mg/kg i.p.) or vehicle was given 30 min after MCAO </plain></SENT>
<SENT sid="3" pm="."><plain>The lesions were examined with magnetic resonance imaging (MRI), tri-<z:chebi fb="1" ids="30396">phenyl</z:chebi> tetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> (TTC) staining and the functional outcome was determined using neurological scoring according to Bederson et al </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: PP2-treated rats showed approximately 50% reduction of <z:mpath ids='MPATH_124'>infarct</z:mpath> size on T2-weighted MRI and in TTC staining compared with controls (P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Moreover, the neurological score was better in the PP2 group than controls (P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: PP2 is a potential neuroprotective agent in <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>-reperfusion </plain></SENT>
<SENT sid="7" pm="."><plain>The interference of PP2 with SFKs and/or other pathways remains to be elucidated </plain></SENT>
</text></document>